Nvidia disclosed in recent regulatory filings that it had fully exited its roughly two‑year, 7.71 million‑share investment in Recursion Pharmaceuticals, while Cathie Wood’s ARK Invest simultaneously ...

Major investors Nvidia and Novo Holdings A/S have fully exited their positions in Recursion Pharmaceuticals (NasdaqGS:RXRX), signaling a shift in institutional backing. Recursion has acquired full ...

Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.

RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA ...

The OpenClaw episode exposed a risk most security programs are not actively watching for: collusion between AI-driven systems. In one of the first publicly observed instances, autonomous AI agents ...

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

FDA truncates drug approval process; Makary pushes for more OTC drugs; Inside the rocky ride for Recursion Pharmaceuticals.

The new coding model released Thursday afternoon, entitled GPT-5.3-Codex, builds on OpenAI’s GPT-5.2-Codex model and combines insights from the AI company’s GPT-5.2 model, which excels on non-coding ...

Precedence Research, a leading strategic research firm, presents a comprehensive analysis of the AI-driven bioengineering ...

The past is fast losing its reliability as a guide to the future in an age of exponentially evolving AI. As error rates drop ...

Future AI-guided genomic analysis offers the potential to further optimize gene constructs, expression profiles, and performance traits, accelerating the development of next-generation materials.

The art and digital culture festival reminded us that networked, relational structures have a robust tradition outside big ...